Read by QxMD icon Read

Meningococcal vaccinations

Clio A Andreae, Richard B Sessions, Mumtaz Virji, Darryl J Hill
Neisseria meningitidis is an antigenically and genetically variable Gram-negative bacterium and a causative agent of meningococcal meningitis and septicaemia. Meningococci encode many outer membrane proteins, including Opa, Opc, Msf, fHbp and NadA, identified as being involved in colonisation of the host and evasion of the immune response. Although vaccines are available for the prevention of some types of meningococcal disease, none currently offer universal protection. We have used sequences within the Neisseria PubMLST database to determine the variability of msf and opc in 6,500 isolates...
2018: PloS One
A W Dretler, N G Rouphael, D S Stephens
The control of meningitis, meningococcemia and other infections caused by Neisseria meningitidis is a significant global health challenge. Substantial progress has occurred in the last twenty years in meningococcal vaccine development and global implementation. Meningococcal protein-polysaccharide conjugate vaccines to serogroups A, C, W, and Y (modeled after the Haemophilus influenzae b conjugate vaccines) provide better duration of protection and immunologic memory, and overcome weak immune responses in infants and young children and hypo-responsive to repeated vaccine doses seen with polysaccharide vaccines...
March 15, 2018: Human Vaccines & Immunotherapeutics
Scott Vuocolo, Paul Balmer, William C Gruber, Kathrin U Jansen, Annaliesa S Anderson, John L Perez, Laura J York
Routine prophylactic vaccination and mass vaccination strategies have been used to control both endemic and epidemic disease caused by Neisseria meningitidis globally. This review discusses real-world examples of these vaccination strategies, their implementation, and outcomes of these efforts, with the overall goal of providing insights on how to achieve optimal control of meningococcal disease through vaccination in varied settings. Tailoring immunization programs to fit the needs of the target population has the potential to optimally reduce disease incidence...
March 15, 2018: Human Vaccines & Immunotherapeutics
Francelena de Sousa Silva, Yonna Costa Barbosa, Mônica Araújo Batalha, Marizélia Rodrigues Costa Ribeiro, Vanda Maria Ferreira Simões, Maria Dos Remédios Freitas Carvalho Branco, Érika Bárbara Abreu Fonseca Thomaz, Rejane Christine de Sousa Queiroz, Waleska Regina Machado Araújo, Antônio Augusto Moura da Silva
This study estimated the percentages of incomplete immunization with new vaccines and old vaccines and associated factors in children 13 to 35 months of age belonging to a birth cohort in São Luís, the capital of Maranhão State, Brazil. The sample was probabilistic, with 3,076 children born in 2010. Information on vaccination was obtained from the Child's Health Card. The new vaccines, namely those introduced in 2010, were meningococcal C and 10-valent pneumococcal, and the old vaccines, or those already on the childhood immunization schedule, were BCG, hepatitis B, human rotavirus, polio, tetravalent (diphtheria, tetanus, pertussis, Haemophilus influenzae b), yellow fever, and triple viral (measles, mumps, rubella)...
March 12, 2018: Cadernos de Saúde Pública
S Hollingshead, I Jongerius, R M Exley, S Johnson, S M Lea, C M Tang
There is an urgent need to develop vaccines against pathogenic bacteria. However, this is often hindered by antigenic diversity and difficulties encountered manufacturing membrane proteins. Here we show how to use structure-based design to develop chimeric antigens (ChAs) for subunit vaccines. ChAs are generated against serogroup B Neisseria meningitidis (MenB), the predominant cause of meningococcal disease in wealthy countries. MenB ChAs exploit factor H binding protein (fHbp) as a molecular scaffold to display the immunogenic VR2 epitope from the integral membrane protein PorA...
March 13, 2018: Nature Communications
Lisa K McNeil, Robert G K Donald, Alexey Gribenko, Roger French, Nathaniel Lambert, Shannon L Harris, Thomas R Jones, Sheng Li, Gary Zlotnick, Ulrich Vogel, Heike Claus, Raquel Abad, Julio A Vazquez, Ray Borrow, Jamie Findlow, Muhamed-Kheir Taha, Ala-Eddine Deghmane, Dominique A Caugant, Paula Kriz, Martin Musilek, Xin Wang, Jeni Vuong, Leonard W Mayer, Michael W Pride, Kathrin U Jansen, Annaliesa S Anderson
Bivalent rLP2086 (Trumenba), a vaccine for prevention of Neisseria meningitidis serogroup B (NmB) disease, was licensed for use in adolescents and young adults after it was demonstrated that it elicits antibodies that initiate complement-mediated killing of invasive NmB isolates in a serum bactericidal assay with human complement (hSBA). The vaccine consists of two factor H binding proteins (fHBPs) representing divergent subfamilies to ensure broad coverage. Although it is the surrogate of efficacy, an hSBA is not suitable for testing large numbers of strains in local laboratories...
March 13, 2018: MBio
M Joseph John, Amrith Mathew, Sunil Bhat, Anushree Prabhakaran, Biju George, Jacob John
BACKGROUND: Hematopoietic stem cell transplant (HSCT) recipients are more susceptible to infections from vaccine preventable diseases (VPDs) than the general population. Indian stem cell transplant registry (ISCTR) post-BMT vaccination guidelines were formulated in 2015. The objective of the survey was to assess the compliance to these guidelines among transplant physicians in India. MATERIALS AND METHODS: This is a cross-sectional survey executed as the quantitative research strategy to explore the various aspects of vaccination practices among transplant physicians in India...
March 9, 2018: Vaccine
Daniela Beltrami, Pierre Guilcher, David Longchamp, Pierre Alex Crisinel
Acute epiglottitis is a severe and potentially life-threatening condition. Since the implementation of Haemophilus influenzae vaccination, the number of cases of epiglottitis has decreased and the proportion of other infectious causes has increased. We report a case of acute epiglottitis in a teenager caused by Neisseria meningitidis , an unusual pathogen.
March 5, 2018: BMJ Case Reports
Domenico Martinelli, Francesca Fortunato, Stefania Iannazzo, Maria Giovanna Cappelli, Rosa Prato
Background: Vaccine-preventable diseases among high-risk patients are a public health priority in high-income countries. Most national immunization programs have included vaccination recommendations for these population groups but they remain hard-to-reach and coverage data are poorly available. In a pilot study, we developed and tested an automated approach for identifying individuals with underlying medical conditions to feed an immunization information system (IIS). Methods: We reviewed published recommendations on medical conditions that indicate vaccination against influenza, pneumococcal disease, meningococcal disease, hepatitis A, and hepatitis B...
2018: Frontiers in Public Health
Clare L Cutland, Terry Nolan, Scott A Halperin, Zafer Kurugol, Khatija Ahmed, Kirsten P Perrett, Peter Richmond, Helen S Marshall, Mehmet Ceyhan, Devayani Kolhe, Marjan Hezareh, Marie Van Der Wielen
BACKGROUND: We evaluated the immunogenicity and safety of 1 and 2 doses of quadrivalent meningococcal serogroup A, C, W and Y tetanus toxoid-conjugate vaccine (MenACWY-TT) given alone or co-administered with 13-valent pneumococcal conjugate vaccine (PCV13) in toddlers. METHODS: In this phase III, open-label, controlled, multicentre study (NCT01939158), healthy toddlers aged 12-14 months were randomised into 4 groups to receive 1 dose of MenACWY-TT at month (M) 0 (ACWY_1), 2 doses of MenACWY-TT at M0 and M2 (ACWY_2), MenACWY-TT and PCV13 at M0 (Co-ad), or PCV13 at M0 and MenACWY-TT at M2 (PCV13/ACWY)...
March 1, 2018: Vaccine
Sandra Manzanares-Laya, Oleguer Parés-Badell, Pilar Gorrindo, Pere Simón, Miriam Ros, Anna de Andrés, Núria López Segura, Sonia Brió Sanagustín, Anna Vilella, Carlos Rodrigo Gonzalo de Liria, Àngels Orcau, Joan A Caylà
INTRODUCTION AND OBJECTIVE: The purpose of this study was to describe the evolution of meningococcal disease (MD) in the city of Barcelona between 1988 and 2015 and to assess the impact of the vaccine against serogroup C. MATERIALS AND METHODOLOGY: The evolution of MD and by serogroup was analysed using the information included in the mandatory notification diseases registry. Incidences of all serogroups between the periods of before and after the implementation of the serogroup C vaccine in 2000 were compared...
March 1, 2018: Medicina Clínica
Marcie Fisher-Borne, Alexander J Preiss, Molly Black, Kate Roberts, Debbie Saslow
OBJECTIVE: Human papillomavirus (HPV) vaccine coverage in the United States remains low compared with other adolescent vaccines. As the largest primary care network in the United States, safety net clinics such as federally qualified health centers (FQHCs) serve patients at a disproportionate risk of HPV-related cancers. In this pilot project, the American Cancer Society (ACS) leveraged its primary care workforce to implement quality improvement interventions in the unique context of 30 FQHC systems across the country, including 130 clinic sites reaching >20,000 adolescents in a variety of geographic settings...
March 2018: Academic Pediatrics
Gregory Zimet, Brian E Dixon, Shan Xiao, Wanzhu Tu, Amit Kulkarni, Tamara Dugan, Meena Sheley, Stephen M Downs
OBJECTIVE: To evaluate the effects of simple and elaborated health care provider (HCP) reminder prompts on human papillomavirus (HPV) vaccine initiation rates. METHODS: Twenty-nine pediatric HCPs serving 5 pediatric clinics were randomized to 1 of 3 arms: 1) usual practice control, 2) simple reminder prompt, and 3) elaborated reminder prompt, which included suggested language for recommending the early adolescent platform vaccines. Prompts were delivered via a computer-based clinical decision support system deployed in the 5 clinics...
March 2018: Academic Pediatrics
Pumtiwitt C McCarthy, Abeer Sharyan, Laleh Sheikhi Moghaddam
Neisseria meningitidis causes most cases of bacterial meningitis. Meningococcal meningitis is a public health burden to both developed and developing countries throughout the world. There are a number of vaccines (polysaccharide-based, glycoconjugate, protein-based and combined conjugate vaccines) that are approved to target five of the six disease-causing serogroups of the pathogen. Immunization strategies have been effective at helping to decrease the global incidence of meningococcal meningitis. Researchers continue to enhance these efforts through discovery of new antigen targets that may lead to a broadly protective vaccine and development of new methods of homogenous vaccine production...
February 25, 2018: Vaccines
M Giuliani, E Bartolini, B Galli, L Santini, P Lo Surdo, F Buricchi, M Bruttini, B Benucci, N Pacchiani, L Alleri, D Donnarumma, W Pansegrau, I Peschiera, I Ferlenghi, R Cozzi, N Norais, M M Giuliani, D Maione, M Pizza, R Rappuoli, O Finco, V Masignani
4CMenB is the first broad coverage vaccine for the prevention of invasive meningococcal disease caused by serogroup B strains. To gain a comprehensive picture of the antibody response induced upon 4CMenB vaccination and to obtain relevant translational information directly from human studies, we have isolated a panel of human monoclonal antibodies from adult vaccinees. Based on the Ig-gene sequence of the variable region, 37 antigen-specific monoclonal antibodies were identified and produced as recombinant Fab fragments, and a subset also produced as full length recombinant IgG1 and functionally characterized...
February 27, 2018: Scientific Reports
Bahaa Abu Raya, Manish Sadarangani
Invasive meningococcal disease causes meningitis and septicemia worldwide with highest rates of disease occurring in children <2 years of age, and in particular young infants. Vaccination during pregnancy has been a successful strategy for prevention of other infections in young infants, most notably tetanus, pertussis and influenza. However, few studies of meningococcal vaccines in pregnancy have been undertaken, and none include the most commonly used current vaccines to prevent disease by capsular groups A, B, C, W and Y...
February 27, 2018: Human Vaccines & Immunotherapeutics
Jessica Healy, Alfonso Rodriguez-Lainz, Laurie D Elam-Evans, Holly A Hill, Sarah Reagan-Steiner, David Yankey
BACKGROUND: An overall increase has been reported in vaccination rates among adolescents during the past decade. Studies of vaccination coverage have shown disparities when comparing foreign-born and U.S.-born populations among children and adults; however, limited information is available concerning potential disparities in adolescents. METHODS: The National Immunization Survey-Teen is a random-digit-dialed telephone survey of caregivers of adolescents aged 13-17 years, followed by a mail survey to vaccination providers that is used to estimate vaccination coverage among the U...
February 23, 2018: Vaccine
Joan L Robinson
Invasive meningococcal disease (IMD) is serious, often resulting in fulminant sepsis or meningitis. IMD in Canada is primarily attributable to serogroups B and C. There are routine programs for serogroup C vaccine at 12 months of age, with some jurisdictions routinely providing additional earlier doses. Adolescents routinely receive a booster dose of serogroup C vaccine or of a quadrivalent (serogroups A, C, W and Y) vaccine. Serogroup B vaccines are not recommended for routine use pending further data on the efficacy and duration of protection from the available vaccine...
February 2018: Paediatrics & Child Health
Serina Padilla, Gretchen Homan, Matt Engel, Carolyn R Ahlers-Schmidt, Kari Harris
Background: Kansas falls consistently below average for adolescent vaccination of meningococcal (MCV), human papillomavirus (HPV), and influenza. Methods: For this study, the members of Kansas Chapter of the American Academy of Pediatrics were emailed a confidential electronic survey soliciting their impressions of vaccination in their practice. Results: Of 137 providers emailed, 61 (45%) completed the survey. Thirteen providers were excluded as they did not see/vaccinate adolescents or did not complete the survey...
November 2017: Kansas Journal of Medicine
Alicia Arnott, Penelope Jones, Lucinda J Franklin, Denis Spelman, Karin Leder, Allen C Cheng
Background: Overwhelming post-splenectomy infection (OPSI) is a serious complication of asplenia. Clinical guidelines recommend a number of measures to reduce the risk of OPSI, but awareness and adherence to preventative measures is generally poor. We aimed to determine whether a registry for asplenic/hyposplenic patients was associated with a reduction in the incidence of infection with encapsulated bacteria. Methods: We performed a retrospective cohort study of asplenic/hyposplenic patients in the state of Victoria, Australia who registered with Spleen Australia from 2003 - 2014...
February 17, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"